Trovagene Investor Relations Trovagene Investor Relations Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018 -Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT Thu, 18 Oct 2018 05:30:00 -0700 Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib Wed, 03 Oct 2018 05:30:00 -0700 Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial Thu, 27 Sep 2018 05:30:00 -0700 Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones Tue, 18 Sep 2018 05:30:00 -0700 Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response Wed, 05 Sep 2018 05:00:00 -0700